Related Experiment Video

Updated: Oct 9, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.9K

Emerging Therapeutic Agents for Colorectal Cancer

Marianna Nalli1, Michela Puxeddu1, Giuseppe La Regina1

  • 1Department of Drug Chemistry and Technologies, Sapienza University of Rome, 00185 Rome, Italy.

Molecules (Basel, Switzerland)
|December 24, 2021
PubMed

Insights

New therapeutic agents, including small-molecule inhibitors and immune checkpoint blockers, show promise for colorectal cancer (CRC) patients. These emerging treatments target key pathways and offer potential benefits for those with unmet medical needs.

Area of Science:

  • Oncology
  • Pharmacology
  • Immunotherapy

Background:

  • Colorectal cancer (CRC) remains a significant health concern with ongoing needs for effective treatments.
  • Existing therapies for CRC have limitations, necessitating the development of novel therapeutic strategies.

Purpose of the Study:

  • To review emerging therapeutic agents for colorectal cancer (CRC) with demonstrated potential in clinical practice.
  • To provide an overview of recent advances in targeted therapies and immunotherapies for CRC.

Main Methods:

  • Literature review focusing on recent advances in CRC therapeutics.
  • Analysis of small-molecule inhibitors (tyrosine kinase inhibitors, BRAF/MEK inhibitors, STAT3 inhibitors) and immune checkpoint blockers (PD1/PDL-1 inhibitors).

Main Results:

  • Tyrosine kinase inhibitors targeting VEGF and KIT, BRAF and MEK inhibitors, TLR9 agonists, STAT3 inhibitors, and PD1/PDL-1 inhibitors are among the promising agents.
  • These agents target specific molecular pathways implicated in CRC progression.
  • Recent advances indicate potential clinical utility for these novel agents.

Conclusions:

  • Emerging therapeutic agents offer new hope for colorectal cancer patients, particularly those with unmet medical needs.
  • Targeted therapies and immunotherapies represent a significant advancement in CRC treatment paradigms.
  • Continued research and clinical trials are crucial to fully realize the potential of these novel agents.
Keywords:
CRCanticancer agentscanceremerging targets

More Related Videos

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.7K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
262
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
230
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
283